Hemoglobin Variant Separation Using Glycine Buffer Eluents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring hemoglobin variants, such as HPLC, are limited in their ability to accurately separate and measure abnormal hemoglobins and markers for thalassemia beyond HbA1c, HbF, HbA0, HbS, and HbC, lacking the precision needed for comprehensive hemoglobin analysis.
Innovation Solution
A high-performance liquid chromatography method using specific eluents with defined compositions of phosphoric acid monohydrogen and dihydrogen metal salts, allowing for the accurate measurement of a broader range of hemoglobin variants, including HbBart's, HbH, HbA2, HbE, HbD, HbS, HbC, and HbConstantSpring, by optimizing the eluent's components and osmotic pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional HPLC methods using phosphoric acid-based buffer solutions are used, then HbA1c, HbF, and HbA0 can be separated, but other hemoglobin variants including abnormal hemoglobin and thalassemia markers cannot be adequately separated
Solution Approach 1:
The invention changes the chemical parameters of the eluent by using a glycine-based buffer system with specific pH ranges (pH 2.0-3.5 for abnormal hemoglobin, pH 8.5-9.5 for thalassemia markers) instead of conventional phosphoric acid buffers. This parameter change enables the separation of a broader range of hemoglobin variants including HbS, HbC, HbE, HbD, HbG, HbO, HbA2, HbF, and HbA0 that cannot be adequately separated by conventional methods
Solution Approach 2:
The invention employs a composite eluent system combining glycine buffer with specific additives (such as lithium hydroxide, sodium hydroxide, or potassium hydroxide) to create a multi-component solution that provides both the buffering capacity and the specific ionic conditions needed to separate diverse hemoglobin variants with different charge properties and stability characteristics
2Measurement precision
If multiple separate measurements are performed for different hemoglobin variants, then comprehensive analysis can be achieved, but measurement time and operational complexity increase
Solution Approach 1:
The invention creates a universal measurement system where a single HPLC apparatus configured with the glycine-based eluent system can simultaneously separate and measure all types of hemoglobin variants (normal, abnormal, and thalassemia markers) in one continuous run. The system achieves multi-functionality by using pH gradient elution and appropriate column selection to handle diverse hemoglobin types without requiring method changes or multiple separate measurements
3Ease of manufacture
If conventional eluents are used, then standard hemoglobin variants can be measured, but abnormal hemoglobin and thalassemia markers require specialized conditions not provided by standard eluents
Solution Approach 1:
The invention establishes specific parameter ranges for the glycine-based eluent (pH 2.0-3.5 for abnormal hemoglobin separation, pH 8.5-9.5 for thalassemia markers) that provide reliable separation conditions. These parameter specifications ensure consistent and reproducible separation results for abnormal hemoglobin variants and thalassemia markers while maintaining ease of eluent preparation from readily available chemicals
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the precise separation and measurement of multiple hemoglobin variants, improving diagnostic accuracy for diabetes and thalassemia, reducing the need for multiple measurements and enhancing clinical laboratory testing.
Implementation Method 1
performing high-performance liquid chromatography using an eluent
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a method of measuring at least one kind of hemoglobin, selected from abnormal hemoglobin, or hemoglobin that is a marker for thalassemia, the method comprising: performing high-performance liquid chromatography, using: an eluent L that contains a phosphoric acid monohydrogen dialkali metal salt (component 1) and a phosphoric acid dihydrogen monoalkali metal salt (component 2) as components, and that has a content of component 1 of from 0.08% by mass to 0.50% by mass with respect to a total mass of the eluent L, a content of component 2 of from 0.04% by mass to 1.2% by mass with respect to a total mass of the eluent L, and a ratio of component 2/component 1 of from 0.4 to 10.